ArticleCancer cell international2026
SPIB suppresses protective autophagy via the IFIT2/PINK1/Parkin axis to promote anoikis in colorectal cancer.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAnoikis is a critical mechanism that suppresses tumor metastasis. However, cancer cells evade anoikis by activating protective autophagy, thereby promoting metastasis. Although SPIB acts as a tumor suppressor in multiple cancers, its role in regulating autophagy-mediated anoikis resistance in colorectal cancer (CRC) remains unclear. This study aimed to investigate the impact of SPIB on anoikis resistance in CRC cells.
methodsBioinformatics analysis was employed to screen key genes regulating anoikis resistance in CRC. Stable SPIB knockdown/overexpression cell lines were constructed, and in vitro/in vivo experiments were conducted to examine SPIB's biological functions in CRC. Mechanistic insights were obtained via CCK-8, EdU, Transwell, CUT&Tag-seq, RNA-seq, dual-luciferase reporter assays, and mitochondrial membrane potential assays.
resultsSPIB expression was significantly reduced in CRC tissues and cell lines. Functionally, SPIB inhibited CRC progression both in vitro and in vivo. Mechanistically, SPIB transcriptionally activated IFIT2, which subsequently restored mitochondrial membrane potential(ΔΨm), thereby inhibiting protective autophagy through the PINK1/Parkin pathway and sensitizing CRC cells to anoikis.
conclusionOur results demonstrate that SPIB exerts tumor-suppressive effects during CRC invasion and metastasis through the IFIT2/PINK1/Parkin axis. This study highlights SPIB as a potential therapeutic target for overcoming anoikis resistance in CRC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.